SCHEMBL3017017

SCHEMBL3017017

COc1cccc(Cc2csc(N3CCC(S(=O)(=O)c4c(C)c(C)cc(C)c4C)CC3)n2)c1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.41
ALDH1A1 P00352 5/20 0.41
LMNA P02545 4/20 0.41
HSD17B10 Q99714 3/20 0.41
HPGD P15428 1/20 0.41
PTPRB P23467 1/20 0.38
MAPK1 P28482 2/20 0.38
USP2 O75604 1/20 0.38
RECQL P46063 1/20 0.38
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.38
KMT2A Q03164 6/20 0.38
MEN1 O00255 5/20 0.38
ALPL P05186 1/20 0.36
CES2 O00748 1/20 0.36
F2RL3 Q96RI0 3/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015787 0.91 MAPT (0.41) MAPTALDH1A1LMNAHSD17B10HPGD
SCHEMBL3012717 0.91 F2RL3 (0.37) F2RL3SMN1; SMN2
SCHEMBL3016610 0.90 RAB9A (0.40) MAPTALDH1A1KMT2AMEN1F2RL3
SCHEMBL3006205 0.89 DNM1L (0.39) MAPTKMT2AMEN1
SCHEMBL3004414 0.89 MAPT (0.42) MAPTALDH1A1LMNAHSD17B10HPGD
SCHEMBL3008927 0.89 MAPT (0.42) MAPTALDH1A1LMNAHSD17B10HPGD
SCHEMBL3015317 0.88 KMT2A (0.37) TP53KMT2AMEN1
SCHEMBL2998099 0.88 DNM1L (0.42) ALDH1A1LMNAHSD17B10MAPK1KMT2A
SCHEMBL3012372 0.87 MAPT (0.42) MAPTALDH1A1LMNAHSD17B10HPGD
SCHEMBL3012843 0.87 SMN1; SMN2 (0.37) MAPTALDH1A1LMNAHPGDRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885ALDH1A1 3510/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.